{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:11:28Z","timestamp":1791443488100,"version":"4.3.3"},"reference-count":70,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL126028"],"award-info":[{"award-number":["R01HL126028"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL127694"],"award-info":[{"award-number":["R01HL127694"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["P01HL092969"],"award-info":[{"award-number":["P01HL092969"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL45095"],"award-info":[{"award-number":["R01HL45095"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL73029"],"award-info":[{"award-number":["R01HL73029"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["P01HL128203"],"award-info":[{"award-number":["P01HL128203"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL144558"],"award-info":[{"award-number":["R01HL144558"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R35HL135833"],"award-info":[{"award-number":["R35HL135833"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK017047"],"award-info":[{"award-number":["P30DK017047"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DP3DK108209"],"award-info":[{"award-number":["DP3DK108209"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:p>Diabetes is now a pandemic disease. Moreover, a large number of people with prediabetes are at risk for developing frank diabetes worldwide. Both type 1 and type 2 diabetes increase the risk of atherosclerotic cardiovascular disease (CVD). Even with statin treatment to lower LDL cholesterol, patients with diabetes have a high residual CVD risk. Factors mediating the residual risk are incompletely characterized. An attractive hypothesis is that remnant lipoprotein particles (RLPs), derived by lipolysis from VLDL and chylomicrons, contribute to this residual risk. RLPs constitute a heterogeneous population of lipoprotein particles, varying markedly in size and composition. Although a universally accepted definition is lacking, for the purpose of this review we define RLPs as postlipolytic partially triglyceride-depleted particles derived from chylomicrons and VLDL that are relatively enriched in cholesteryl esters and apolipoprotein (apo)E. RLPs derived from chylomicrons contain apoB48, while those derived from VLDL contain apoB100. Clarity as to the role of RLPs in CVD risk is hampered by lack of a widely accepted definition and a paucity of adequate methods for their accurate and precise quantification. New specific methods for RLP quantification would greatly improve our understanding of their biology and role in promoting atherosclerosis in diabetes and other disorders.<\/jats:p>","DOI":"10.2337\/dbi19-0007","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:20:58Z","timestamp":1584750058000},"page":"508-516","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":223,"title":["Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease"],"prefix":"10.2337","volume":"69","author":[{"given":"Alan","family":"Chait","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-3592","authenticated-orcid":false,"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine and Nutrition, Department of Medicine, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Vaisar","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay W.","family":"Heinecke","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira J.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-6523","authenticated-orcid":false,"given":"Karin E.","family":"Bornfeldt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA"},{"name":"Department of Pathology, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"2022031303310609300_B1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2022031303310609300_B2","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.2337\/dc14-1720","article-title":"Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association","volume":"37","author":"de Ferranti","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031303310609300_B3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031303310609300_B4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/ATVBAHA.116.306256","article-title":"Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus","volume":"37","author":"Yahagi","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031303310609300_B5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","article-title":"Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials","volume":"52","author":"Nicholls","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022031303310609300_B6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/db16-0046","article-title":"Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol","volume":"65","author":"Xiao","year":"2016","journal-title":"Diabetes"},{"key":"2022031303310609300_B7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev"},{"key":"2022031303310609300_B8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/nu5030981","article-title":"Hypertriglyceridemia","volume":"5","author":"Brahm","year":"2013","journal-title":"Nutrients"},{"key":"2022031303310609300_B9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2337\/diacare.14.9.839","article-title":"Relationship to atherogenesis","volume":"14","author":"Ginsberg","year":"1991","journal-title":"Diabetes Care"},{"key":"2022031303310609300_B10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1172\/JCI107331","article-title":"I. Lipid levels in 500 survivors of myocardial infarction","volume":"52","author":"Goldstein","year":"1973","journal-title":"J Clin Invest"},{"key":"2022031303310609300_B11","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"2022031303310609300_B12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"2022031303310609300_B13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"2022031303310609300_B14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/VHRM.S104369","article-title":"Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease","volume":"12","author":"Toth","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"2022031303310609300_B15","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"2022031303310609300_B16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.11.065","article-title":"Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III","volume":"69","author":"Pechlaner","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022031303310609300_B17","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1172\/JCI127308","article-title":"Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes","volume":"130","author":"Kanter","year":"2019","journal-title":"J Clin Invest"},{"key":"2022031303310609300_B18","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1194\/jlr.P090647","article-title":"Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D","volume":"60","author":"Basu","year":"2019","journal-title":"J Lipid Res"},{"key":"2022031303310609300_B19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/ATVBAHA.111.238493","article-title":"Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations","volume":"32","author":"Ooi","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031303310609300_B20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI115402","article-title":"Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families","volume":"88","author":"Sprecher","year":"1991","journal-title":"J Clin Invest"},{"key":"2022031303310609300_B21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/01.RES.33.6.633","article-title":"A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins","volume":"33","author":"Zilversmit","year":"1973","journal-title":"Circ Res"},{"key":"2022031303310609300_B22","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.90.5.2069","article-title":"Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans","volume":"90","author":"Schneeman","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031303310609300_B23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1172\/JCI107171","article-title":"Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man","volume":"52","author":"Havel","year":"1973","journal-title":"J Clin Invest"},{"key":"2022031303310609300_B24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1172\/JCI108130","article-title":"Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat","volume":"56","author":"Mjos","year":"1975","journal-title":"J Clin Invest"},{"key":"2022031303310609300_B25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1172\/JCI109435","article-title":"Quantitation of the transfer of surface phospholipid of chylomicrons to the high density lipoprotein fraction during the catabolism of chylomicrons in the rat","volume":"64","author":"Redgrave","year":"1979","journal-title":"J Clin Invest"},{"key":"2022031303310609300_B26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2006.04.023","article-title":"LDL composition in E2\/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes","volume":"192","author":"Murdoch","year":"2007","journal-title":"Atherosclerosis"},{"key":"2022031303310609300_B27","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0140-6736(77)92717-9","article-title":"Type-III hyperlipoproteinaemia (\u201cremnant removal disease\u201d). Insight into the pathogenetic mechanism","volume":"1","author":"Chait","year":"1977","journal-title":"Lancet"},{"key":"2022031303310609300_B28","first-page":"3236","article-title":"Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice","volume":"119","author":"Stanford","year":"2009","journal-title":"J Clin Invest"},{"key":"2022031303310609300_B29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/01.ATV.6.1.79","article-title":"Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects","volume":"6","author":"Musliner","year":"1986","journal-title":"Arteriosclerosis"},{"key":"2022031303310609300_B30","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/BF01489475","article-title":"Evaluation of the classical methods for the diagnosis of type III hyperlipoproteinemia","volume":"55","author":"Patsch","year":"1977","journal-title":"Klin Wochenschr"},{"key":"2022031303310609300_B31","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1172\/JCI106403","article-title":"Abnormal lipid composition of chylomicrons in broad-beta disease (type 3hyperlipoproteinemia)","volume":"49","author":"Hazzard","year":"1970","journal-title":"J Clin Invest"},{"key":"2022031303310609300_B32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-2275(20)41527-5","article-title":"Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100","volume":"33","author":"Campos","year":"1992","journal-title":"J Lipid Res"},{"key":"2022031303310609300_B33","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/clinchem\/44.12.2490","article-title":"Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma","volume":"44","author":"Leary","year":"1998","journal-title":"Clin Chem"},{"key":"2022031303310609300_B34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cca.2016.12.011","article-title":"Triglyceride content in remnant lipoproteins is significantly increased after food intake and is associated with plasma lipoprotein lipase","volume":"465","author":"Nakajima","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2022031303310609300_B35","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1373\/clinchem.2007.092296","article-title":"Development of a homogeneous assay to measure remnant lipoprotein cholesterol","volume":"53","author":"Miyauchi","year":"2007","journal-title":"Clin Chem"},{"key":"2022031303310609300_B36","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1373\/clinchem.2009.133934","article-title":"Limitations of automated remnant lipoprotein cholesterol assay for diagnostic use","volume":"55","author":"Schaefer","year":"2009","journal-title":"Clin Chem"},{"key":"2022031303310609300_B37","doi-asserted-by":"crossref","first-page":"II21","DOI":"10.1002\/clc.4960221405","article-title":"Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy","volume":"22","author":"Otvos","year":"1999","journal-title":"Clin Cardiol"},{"key":"2022031303310609300_B38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2019.05.011","article-title":"A third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals","volume":"286","author":"Balling","year":"2019","journal-title":"Atherosclerosis"},{"key":"2022031303310609300_B39","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1373\/clinchem.2007.100586","article-title":"Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis","volume":"54","author":"Caulfield","year":"2008","journal-title":"Clin Chem"},{"key":"2022031303310609300_B40","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1373\/clinchem.2014.228114","article-title":"Quantification of HDL particle concentration by calibrated ion mobility analysis","volume":"60","author":"Hutchins","year":"2014","journal-title":"Clin Chem"},{"key":"2022031303310609300_B41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/B978-0-12-800263-6.00003-3","article-title":"Apolipoprotein B-48: a unique marker of chylomicron metabolism","volume":"64","author":"Nakajima","year":"2014","journal-title":"Adv Clin Chem"},{"key":"2022031303310609300_B42","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1373\/clinchem.2016.268938","article-title":"A new start for triglycerides and remnant cholesterol-nonfasting","volume":"63","author":"Nordestgaard","year":"2017","journal-title":"Clin Chem"},{"key":"2022031303310609300_B43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7326\/0003-4819-82-2-158","article-title":"The biochemical, clinical, and genetic features of type III hyperlipoproteinemia","volume":"82","author":"Morganroth","year":"1975","journal-title":"Ann Intern Med"},{"key":"2022031303310609300_B44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.atherosclerosis.2015.02.046","article-title":"Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study","volume":"240","author":"Koopal","year":"2015","journal-title":"Atherosclerosis"},{"key":"2022031303310609300_B45","first-page":"1195","article-title":"Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism","volume-title":"The Metabolic Basis of Inherited Disease","author":"Mahley","year":"1989"},{"key":"2022031303310609300_B46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MED.0000000000000316","article-title":"Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder","volume":"24","author":"Koopal","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2022031303310609300_B47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.1991.tb00428.x","article-title":"Expression of type III hyperlipoproteinaemia in a subject with secondary hypothyroidism bearing the apolipoprotein E2\/2 phenotype","volume":"230","author":"Feussner","year":"1991","journal-title":"J Intern Med"},{"key":"2022031303310609300_B48","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0026-0495(78)90151-8","article-title":"Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia","volume":"27","author":"Chait","year":"1978","journal-title":"Metabolism"},{"key":"2022031303310609300_B49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.atherosclerosis.2016.01.009","article-title":"The relation between apolipoprotein E (APOE) genotype and peripheral artery disease in patients at high risk for cardiovascular disease","volume":"246","author":"Koopal","year":"2016","journal-title":"Atherosclerosis"},{"key":"2022031303310609300_B50","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(08)60768-0","article-title":"Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies","volume":"371","author":"Mazzone","year":"2008","journal-title":"Lancet"},{"key":"2022031303310609300_B51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0140-6736(87)92734-6","article-title":"Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men","volume":"2","author":"Krauss","year":"1987","journal-title":"Lancet"},{"key":"2022031303310609300_B52","doi-asserted-by":"crossref","first-page":"8783","DOI":"10.1016\/S0021-9258(17)39420-6","article-title":"Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages","volume":"260","author":"Van Lenten","year":"1985","journal-title":"J Biol Chem"},{"key":"2022031303310609300_B53","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1161\/01.ATV.17.9.1707","article-title":"Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation","volume":"17","author":"Whitman","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031303310609300_B54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/B978-0-12-801238-3.65798-7","article-title":"Dyslipidemia in diabetes","volume-title":"Encyclopedia of Endocrine Diseases","author":"Subramanian","year":"2019","edition":"2nd ed"},{"key":"2022031303310609300_B55","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"key":"2022031303310609300_B56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.diabet.2009.04.004","article-title":"Lipid disorders in type 1 diabetes","volume":"35","author":"Verg\u00e8s","year":"2009","journal-title":"Diabetes Metab"},{"key":"2022031303310609300_B57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1056-8727(01)00199-4","article-title":"Atherogenic lipoproteins and diabetes mellitus","volume":"16","author":"Yoshino","year":"2002","journal-title":"J Diabetes Complications"},{"key":"2022031303310609300_B58","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/ATVBAHA.111.241356","article-title":"Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling","volume":"32","author":"Moon","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031303310609300_B59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tem.2013.04.001","article-title":"The regulation of ApoB metabolism by insulin","volume":"24","author":"Haas","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"2022031303310609300_B60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.atherosclerosis.2008.07.046","article-title":"Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance","volume":"204","author":"Laatsch","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022031303310609300_B61","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"key":"2022031303310609300_B62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2265.2003.01731.x","article-title":"Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus","volume":"58","author":"Dane-Stewart","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2022031303310609300_B63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0026-0495(77)90093-2","article-title":"Clearance of chylomicron triacylglycerol and cholesteryl ester from the plasma of streptozotocin-induced diabetic and hypercholesterolemic hypothyroid rats","volume":"26","author":"Redgrave","year":"1977","journal-title":"Metabolism"},{"key":"2022031303310609300_B64","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2337\/diab.35.8.933","article-title":"Apolipoprotein E-containing lipoproteins and lipoprotein remnants in experimental canine diabetes","volume":"35","author":"Wilson","year":"1986","journal-title":"Diabetes"},{"key":"2022031303310609300_B65","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2337\/diab.41.3.325","article-title":"Chylomicron and chylomicron remnant metabolism in STZ-induced diabetic rats","volume":"41","author":"Staprans","year":"1992","journal-title":"Diabetes"},{"key":"2022031303310609300_B66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9150(99)00341-X","article-title":"Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats","volume":"149","author":"Proctor","year":"2000","journal-title":"Atherosclerosis"},{"key":"2022031303310609300_B67","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5551\/jat1994.1.98","article-title":"Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages","volume":"1","author":"Tomono","year":"1994","journal-title":"J Atheroscler Thromb"},{"key":"2022031303310609300_B68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031303310609300_B69","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4158\/EP161445.RA","article-title":"Triglycerides, atherosclerosis, and cardiovascular outcome studies: focus on omega-3 fatty acids","volume":"23","author":"Handelsman","year":"2017","journal-title":"Endocr Pract"},{"key":"2022031303310609300_B70","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/diabetes.diabetesjournals.org\/syndication\/doi\/10.2337\/dbi19-0007","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/69\/4\/508\/434853\/dbi190007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/69\/4\/508\/434853\/dbi190007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:39:41Z","timestamp":1667407181000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/69\/4\/508\/40613\/Remnants-of-the-Triglyceride-Rich-Lipoproteins"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,3,16]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi19-0007","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]}}}